FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316926665> ?p ?o ?g. }

• W4316926665 endingPage "e262" @default.
• W4316926665 startingPage "e254" @default.
• W4316926665 abstract "Tyrosine kinase inhibitors remain a cornerstone in managing metastatic clear cell renal cell carcinoma (RCC). The 4 weeks on/2 weeks off intermittent sunitinib schedule could result in rebound angiogenesis and tumor progression in the 2-week rest period. We propose using bevacizumab during this period for continuous antiangiogenic effects.This was a phase I/II study of patients with advanced clear cell RCC. Sunitinib was given 50 mg daily on a 4-week on/2-week off schedule. Bevacizumab was given on day 29 of each sunitinib cycle. The bevacizumab starting dose was 5 mg/kg, and the dose was escalated to 10 mg if there was no dose-limiting toxicity. The primary endpoints were response rate and progression-free survival (PFS).Twenty-five patients were recruited. The study was closed prematurely because of poor accrual. No dose-limiting toxicity was observed with 5 mg bevacizumab. One patient achieved a complete response, and 12 achieved a partial response (52% response rate). At a median follow-up of 42.2 months (95%, confidence interval (CI) 32.9 to 51.4), the median PFS duration was 16.5 months (95% CI 4.1-28.8), and the median overall survival time was 33.3 months (95% CI 19.4-47.3). Twenty-two patients (88%) had at least one grade 3 or 4 toxicity; the most common were thrombocytopenia (32%), lymphopenia (32%), hypertension (28%), and fatigue (24%).Continuous angiogenesis blockade by adding bevacizumab to the sunitinib on/off regimen for advanced RCC yields significant antitumor activity with manageable increased toxicity." @default.
• W4316926665 created "2023-01-18" @default.
• W4316926665 creator A5030475154 @default.
• W4316926665 creator A5040329506 @default.
• W4316926665 creator A5040371876 @default.
• W4316926665 creator A5042696306 @default.
• W4316926665 creator A5059027149 @default.
• W4316926665 creator A5067532175 @default.
• W4316926665 creator A5079877688 @default.
• W4316926665 creator A5090751404 @default.
• W4316926665 creator A5090942420 @default.
• W4316926665 date "2023-01-17" @default.
• W4316926665 modified "2023-09-27" @default.
• W4316926665 title "Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial" @default.
• W4316926665 cites W1946476244 @default.
• W4316926665 cites W1972893083 @default.
• W4316926665 cites W2019607817 @default.
• W4316926665 cites W2047871200 @default.
• W4316926665 cites W2068562114 @default.
• W4316926665 cites W2096523159 @default.
• W4316926665 cites W2114148421 @default.
• W4316926665 cites W2115005218 @default.
• W4316926665 cites W2116949558 @default.
• W4316926665 cites W2120113475 @default.
• W4316926665 cites W2129820508 @default.
• W4316926665 cites W2138129102 @default.
• W4316926665 cites W2144538538 @default.
• W4316926665 cites W2147186814 @default.
• W4316926665 cites W2149456801 @default.
• W4316926665 cites W2150452646 @default.
• W4316926665 cites W2153867442 @default.
• W4316926665 cites W2155319477 @default.
• W4316926665 cites W2156114777 @default.
• W4316926665 cites W2160476851 @default.
• W4316926665 cites W2170089147 @default.
• W4316926665 cites W2338351073 @default.
• W4316926665 cites W2619054874 @default.
• W4316926665 cites W2792937256 @default.
• W4316926665 cites W2805060661 @default.
• W4316926665 cites W2899524474 @default.
• W4316926665 cites W2911812451 @default.
• W4316926665 cites W2913745075 @default.
• W4316926665 cites W2997302025 @default.
• W4316926665 cites W3131063362 @default.
• W4316926665 cites W3134949580 @default.
• W4316926665 doi "https://doi.org/10.1093/oncolo/oyac261" @default.
• W4316926665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36648325" @default.
• W4316926665 hasPublicationYear "2023" @default.
• W4316926665 type Work @default.
• W4316926665 citedByCount "1" @default.
• W4316926665 countsByYear W43169266652023 @default.
• W4316926665 crossrefType "journal-article" @default.
• W4316926665 hasAuthorship W4316926665A5030475154 @default.
• W4316926665 hasAuthorship W4316926665A5040329506 @default.
• W4316926665 hasAuthorship W4316926665A5040371876 @default.
• W4316926665 hasAuthorship W4316926665A5042696306 @default.
• W4316926665 hasAuthorship W4316926665A5059027149 @default.
• W4316926665 hasAuthorship W4316926665A5067532175 @default.
• W4316926665 hasAuthorship W4316926665A5079877688 @default.
• W4316926665 hasAuthorship W4316926665A5090751404 @default.
• W4316926665 hasAuthorship W4316926665A5090942420 @default.
• W4316926665 hasBestOaLocation W43169266651 @default.
• W4316926665 hasConcept C126322002 @default.
• W4316926665 hasConcept C126894567 @default.
• W4316926665 hasConcept C141071460 @default.
• W4316926665 hasConcept C143998085 @default.
• W4316926665 hasConcept C2776694085 @default.
• W4316926665 hasConcept C2777288759 @default.
• W4316926665 hasConcept C2777472916 @default.
• W4316926665 hasConcept C2777802072 @default.
• W4316926665 hasConcept C2779490328 @default.
• W4316926665 hasConcept C2781413609 @default.
• W4316926665 hasConcept C29730261 @default.
• W4316926665 hasConcept C71924100 @default.
• W4316926665 hasConcept C90924648 @default.
• W4316926665 hasConcept C98274493 @default.
• W4316926665 hasConceptScore W4316926665C126322002 @default.
• W4316926665 hasConceptScore W4316926665C126894567 @default.
• W4316926665 hasConceptScore W4316926665C141071460 @default.
• W4316926665 hasConceptScore W4316926665C143998085 @default.
• W4316926665 hasConceptScore W4316926665C2776694085 @default.
• W4316926665 hasConceptScore W4316926665C2777288759 @default.
• W4316926665 hasConceptScore W4316926665C2777472916 @default.
• W4316926665 hasConceptScore W4316926665C2777802072 @default.
• W4316926665 hasConceptScore W4316926665C2779490328 @default.
• W4316926665 hasConceptScore W4316926665C2781413609 @default.
• W4316926665 hasConceptScore W4316926665C29730261 @default.
• W4316926665 hasConceptScore W4316926665C71924100 @default.
• W4316926665 hasConceptScore W4316926665C90924648 @default.
• W4316926665 hasConceptScore W4316926665C98274493 @default.
• W4316926665 hasIssue "5" @default.
• W4316926665 hasLocation W43169266651 @default.
• W4316926665 hasLocation W43169266652 @default.
• W4316926665 hasLocation W43169266653 @default.
• W4316926665 hasOpenAccess W4316926665 @default.
• W4316926665 hasPrimaryLocation W43169266651 @default.
• W4316926665 hasRelatedWork W1967242542 @default.
• W4316926665 hasRelatedWork W2038639270 @default.

• next